Meeting
2021 ASCO Annual Meeting
Does aggressive surgery only benefit patients with less advanced ovarian cancer?
Authors
Shinichi Tate
Departments of Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
Shinichi Tate , Kyoko Nishikimi , Ayumu Matsuoka , Satoyo Otsuka , Makio Shozu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5556)
DOI
10.1200/JCO.2021.39.15_suppl.5556
Abstract #
5556
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer.
First Author: Travis T. Sims
Poster
2018 ASCO Annual Meeting
Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial).
First Author: Anna Fagotti
Poster
2017 ASCO Annual Meeting
TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO‐OVAR OP7).
First Author: Sven Mahner
First Author: Larissa Meyer